Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study

Rituximab is a standard treatment for non‐Hodgkin diffuse large B‐cell (DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles except for increased administration‐related reacti...

Descripción completa

Detalles Bibliográficos
Autores principales: García‐Muñoz, Ricardo, Quero, Cristina, Pérez‐Persona, Ernesto, Domingo‐García, Abel, Pérez‐López, Cristina, Villaescusa‐de‐la‐Rosa, Teresa, Martínez‐Castro, Ana M., Arguiñano‐Pérez, José M., Parra‐Cuadrado, Juan F., Panizo, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Haematological Malignancy – Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065214/
https://www.ncbi.nlm.nih.gov/pubmed/31573078
http://dx.doi.org/10.1111/bjh.16227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065214/
https://www.ncbi.nlm.nih.gov/pubmed/31573078
http://dx.doi.org/10.1111/bjh.16227

Ejemplares similares